Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor

被引:77
作者
Manshouri, Taghi
Estrov, Zeev
Quintas-Cardama, Alfonso
Burger, Jan
Zhang, Ying
Livun, Ana
Knez, Liza
Harris, David
Creighton, Chad J. [2 ]
Kantarjian, Hagop M.
Verstovsek, Srdan [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA
[2] Baylor Coll Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA
关键词
TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; MUTATION; MYELOFIBROSIS; MICROENVIRONMENT; LEUKEMIA; GROWTH; THROMBOCYTHEMIA;
D O I
10.1158/0008-5472.CAN-10-4002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Signals emanating from the bone marrow microenvironment, such as stromal cells, are thought to support the survival and proliferation of the malignant cells in patients with myeloproliferative neoplasms (MPN). To examine this hypothesis, we established a coculture platform [cells cocultured directly (cell-on-cell) or indirectly (separated by micropore membrane)] designed to interrogate the interplay between Janus activated kinase 2-V617F (JAK2(V617F))-positive cells and the stromal cells. Treatment with atiprimod, a potent JAK2 inhibitor, caused marked growth inhibition and apoptosis of human (SET-2) and mouse (FDCP-EpoR) JAK2(V617F)-positive cells as well as primary blood or bone marrow mononuclear cells from patients with polycythemia vera; however, these effects were attenuated when any of these cell types were cocultured (cell-on-cell) with human marrow stromal cell lines (e.g., HS5, NK. tert, TM-R1). Coculture with stromal cells hampered the ability of atiprimod to inhibit phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. This protective effect was maintained in noncontact coculture assays (JAK2(V617F)-positive cells separated by 0.4-mu m-thick micropore membranes from stromal cells), indicating a paracrine effect. Cytokine profiling of supernatants from noncontact coculture assays detected distinctly high levels of interleukin 6 (IL-6), fibroblast growth factor (FGF), and chemokine C-X-C-motif ligand 10 (CXCL-10)/IFN-gamma-inducible 10-kD protein (IP-10). Anti-IL-6, -FGF, or -CXCL-10/IP-10 neutralizing antibodies ablated the protective effect of stromal cells and restored atiprimod-induced apoptosis of JAK2(V617F)-positive cells. Therefore, our results indicate that humoral factors secreted by stromal cells protect MPN clones from JAK2 inhibitor therapy, thus underscoring the importance of targeting the marrow niche in MPN for therapeutic purposes. Cancer Res; 71(11); 3831-40. (C) 2011 AACR.
引用
收藏
页码:3831 / 3840
页数:10
相关论文
共 23 条
[1]   Contribution of bone microenvironment to leukemogenesis and leukemia progression [J].
Ayala, F. ;
Dewar, R. ;
Kieran, M. ;
Kalluri, R. .
LEUKEMIA, 2009, 23 (12) :2233-2241
[2]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[3]   CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers [J].
Burger, J. A. ;
Peled, A. .
LEUKEMIA, 2009, 23 (01) :43-52
[4]   The microenvironment in mature B-cell malignancies: a target for new treatment strategies [J].
Burger, Jan A. ;
Ghia, Paolo ;
Rosenwald, Andreas ;
Caligaris-Cappio, Federico .
BLOOD, 2009, 114 (16) :3367-3375
[5]   Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors [J].
Hirano, T ;
Ishihara, K ;
Hibi, M .
ONCOGENE, 2000, 19 (21) :2548-2556
[6]   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[7]   Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells [J].
Kawano, Y ;
Kobune, M ;
Yamaguchi, M ;
Nakamura, K ;
Ito, Y ;
Sasaki, K ;
Takahashi, S ;
Nakamura, T ;
Chiba, H ;
Sato, T ;
Matsunaga, T ;
Azuma, H ;
Ikebuchi, K ;
Ikeda, H ;
Kato, J ;
Niitsu, Y ;
Hamada, H .
BLOOD, 2003, 101 (02) :532-540
[8]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[9]   Does primary myelofibrosis involve a defective stem cell niche?: From concept to evidence [J].
Lataillade, Jean-Jacques ;
Pierre-Louis, Olivier ;
Hasselbalch, Hans Carl ;
Uzan, Georges ;
Jasmin, Claude ;
Martyre, Marie-Claire ;
Le Bousse-Kerdiles, Marie-Caroline .
BLOOD, 2008, 112 (08) :3026-3035
[10]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397